{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:01:24Z","timestamp":1768406484362,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"PTC Therapeutics Inc","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"DOI":"10.1186\/s12955-025-02335-5","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:44:02Z","timestamp":1737629042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Estimating health state utilities for aromatic L-amino acid decarboxylase deficiency (AADCd) in the United States"],"prefix":"10.1186","volume":"23","author":[{"given":"Berrin","family":"Monteleone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Forster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gin Nie","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Tomazos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2335_CR1","doi-asserted-by":"crossref","unstructured":"Palma J-A, Norcliffe-Kaufmann L, Fuente C, Percival L, Spalink C, Kaufmann H. 154-Disorders of the autonomic nervous system: autonomic dysfunction in pediatric practice. In: Swaiman KF, Ashwal S, Ferriero DM, Schor NF, Finkel RS, Gropman AL, Pearl PL, Shevell MI, editors. Swaiman\u2019s pediatric neurology. 6th ed. Elsevier; 2017. p. 1173\u201383.","DOI":"10.1016\/B978-0-323-37101-8.00154-5"},{"issue":"1","key":"2335_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymgme.2019.03.009","volume":"127","author":"N Himmelreich","year":"2019","unstructured":"Himmelreich N, Montioli R, Bertoldi M, et al. Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook. Mol Genet Metab. 2019;127(1):12\u201322.","journal-title":"Mol Genet Metab"},{"key":"2335_CR3","doi-asserted-by":"crossref","unstructured":"Himmelreich N, Montioli R, Bertoldi M et al. Corrigendum to Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook [Mol Genet Metab. 2019;127(1):12\u201322]. Mol Genet Metab. 2021;134(1\u20132):216.","DOI":"10.1016\/j.ymgme.2021.06.010"},{"key":"2335_CR4","unstructured":"Whitehead N, Croxford J, Erickson S, Schu MC, Peters M, Hyland K, editors. Estimated prevalence of aromatic l-amino acid decarboxylase (AADC) deficiency in the United States, European Union, and Japan. European Society for Gene and Cell Therapy 26th Annual Congress; 2018; Lausanne, Switzerland."},{"issue":"5","key":"2335_CR5","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/s41390-023-02685-0","volume":"94","author":"JE Park","year":"2023","unstructured":"Park JE, Lee T, Ha K, Cho EH, Ki CS. Carrier frequency and incidence of aromatic L-amino acid decarboxylase deficiency: a gnomAD-based study. Pediatr Res. 2023;94(5):1764\u201370.","journal-title":"Pediatr Res"},{"issue":"4","key":"2335_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2016.05.011","volume":"118","author":"YH Chien","year":"2016","unstructured":"Chien YH, Chen PW, Lee NC, et al. 3-O-methyldopa levels in newborns: result of newborn screening for aromatic l-amino-acid decarboxylase deficiency. Mol Genet Metab. 2016;118(4):259\u201363.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2335_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13023-022-02274-0","volume":"17","author":"K Williams","year":"2022","unstructured":"Williams K, Skrobanski H, Buesch K, Acaster S. Symptoms and impacts of aromatic L-amino acid decarboxylase (AADC) deficiency among individuals with different levels of motor function. Orphanet J Rare Dis. 2022;17(1):128.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2335_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/cns3.20052","volume":"2","author":"A Roubertie","year":"2024","unstructured":"Roubertie A, Anselm I, Ben-Zeev B, et al. Patient selection considerations for AADC deficiency gene therapy. Annals Child Neurol Soc. 2024;2(1):53\u20139.","journal-title":"Annals Child Neurol Soc"},{"issue":"11","key":"2335_CR9","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1080\/03007995.2022.2072090","volume":"38","author":"K Buesch","year":"2022","unstructured":"Buesch K, Zhang R, Szczepa\u0144ska K, et al. Burden and severity of disease of aromatic L-amino acid decarboxylase deficiency: a systematic literature review. Curr Med Res Opin. 2022;38(11):1871\u201382.","journal-title":"Curr Med Res Opin"},{"key":"2335_CR10","unstructured":"European Commission. Upstaza 2022 [updated 12 Mar 2024. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h1653.htm"},{"key":"2335_CR11","unstructured":"Medicines & Healthcare products Regulatory Agency. UPSTAZA 2022 [Available from: https:\/\/www.gov.uk\/government\/publications\/orphan-registered-medicinal-products\/orphan-register#upstaza"},{"issue":"15supplement","key":"2335_CR12","first-page":"S29","volume":"90","author":"Y-H Chien","year":"2018","unstructured":"Chien Y-H, Lee N-C, Tseng S-H, et al. Gene Therapy in Children with AADC Deficiency with AGIL-AADC leads to De Novo Dopamine Production and sustained improvement in Motor milestones over 5 years (S29. 008). Neurology. 2018;90(15supplement):S29.","journal-title":"Neurology"},{"key":"2335_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-publhealth-052120-012811","volume":"43","author":"RM Kaplan","year":"2022","unstructured":"Kaplan RM, Hays RD. Health-Related Quality of Life Measurement in Public Health. Annu Rev Public Health. 2022;43:355\u201373.","journal-title":"Annu Rev Public Health"},{"key":"2335_CR14","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual: NICE process and methods [PMG36]. 2022."},{"key":"2335_CR15","doi-asserted-by":"crossref","unstructured":"Hanbury A, Smith AB, Buesch K. Deriving vignettes for the rare disease AADC deficiency using parent, caregiver and clinician interviews to evaluate the impact on health-related quality of life. Patient Relat Outcome Measures. 2021;12:1\u201312.","DOI":"10.2147\/PROM.S278258"},{"key":"2335_CR16","doi-asserted-by":"crossref","unstructured":"Smith AB, Hanbury A, Buesch K. Eliciting health state utilities for aromatic L-amino acid decarboxylase (AADC) deficiency: a UK vignette study. J patient-reported Outcomes. 2021;5:1\u201310.","DOI":"10.1186\/s41687-021-00403-0"},{"issue":"Suppl 1","key":"2335_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40273-021-01092-9","volume":"40","author":"SH Lo","year":"2022","unstructured":"Lo SH, Gorni K, Sutherland CS, Marti Y, Lloyd A, Paracha N. Preferences and Utilities for Treatment Attributes in type 2 and non-ambulatory type 3 spinal muscular atrophy in the United Kingdom. PharmacoEconomics. 2022;40(Suppl 1):91\u2013102.","journal-title":"PharmacoEconomics"},{"issue":"6","key":"2335_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3233\/JND-210686","volume":"8","author":"A Lloyd","year":"2021","unstructured":"Lloyd A, Aggio D, Slocomb TL, Lee J, Beggs AH, Bilder DA. Estimation of the quality-of-life impact of X-Linked Myotubular Myopathy. J Neuromuscul Dis. 2021;8(6):1047\u201361.","journal-title":"J Neuromuscul Dis"},{"key":"2335_CR19","unstructured":"National Institute for Health and Care Excellence. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency 2023 [Available from: https:\/\/www.nice.org.uk\/guidance\/hst26"},{"issue":"7","key":"2335_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jval.2021.01.011","volume":"24","author":"SA Lipman","year":"2021","unstructured":"Lipman SA, Reckers-Droog VT, Kreimeier S. Think of the children: a discussion of the Rationale for and implications of the perspective used for EQ-5D-Y Health State Valuation. Value Health. 2021;24(7):976\u201382.","journal-title":"Value Health"},{"issue":"1","key":"2335_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12955-021-01858-x","volume":"19","author":"PA Powell","year":"2021","unstructured":"Powell PA, Rowen D, Rivero-Arias O, Tsuchiya A, Brazier JE. Valuing child and adolescent health: a qualitative study on different perspectives and priorities taken by the adult general public. Health Qual Life Outcomes. 2021;19(1):222.","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 1","key":"2335_CR22","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1007\/s10198-013-0508-x","volume":"14","author":"AE Attema","year":"2013","unstructured":"Attema AE, Edelaar-Peeters Y, Versteegh MM, Stolk EA. Time trade-off: one methodology, different methods. Eur J Health Econ. 2013;14(Suppl 1):S53\u201364.","journal-title":"Eur J Health Econ"},{"issue":"8","key":"2335_CR23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1080\/03007995.2021.1932449","volume":"37","author":"K Williams","year":"2021","unstructured":"Williams K, Skrobanski H, Werner C, O\u2019Neill S, Buesch K, Acaster S. Symptoms and impact of aromatic l-amino acid decarboxylase (AADC) deficiency: a qualitative study and the development of a patient-centred conceptual model. Curr Med Res Opin. 2021;37(8):1353\u201361.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"2335_CR24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1080\/03007995.2021.1955668","volume":"37","author":"H Skrobanski","year":"2021","unstructured":"Skrobanski H, Williams K, Werner C, O\u2019Neill S, Buesch K, Acaster S. The impact of caring for an individual with aromatic l-amino acid decarboxylase (AADC) deficiency: a qualitative study and the development of a conceptual model. Curr Med Res Opin. 2021;37(10):1821\u20138.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"2335_CR25","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40273-020-00909-3","volume":"38","author":"JM Ramos-Goni","year":"2020","unstructured":"Ramos-Goni JM, Oppe M, Stolk E, et al. International Valuation Protocol for the EQ-5D-Y-3L. PharmacoEconomics. 2020;38(7):653\u201363.","journal-title":"PharmacoEconomics"},{"key":"2335_CR26","unstructured":"Blakeslee L, Caplan Z, Meyer J, Rabe M, Roberts A. Age and sex composition: 2020. Washington, DC. 2023:C2020BR-06."},{"key":"2335_CR27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-016-0404-1","volume":"34","author":"M Oppe","year":"2016","unstructured":"Oppe M, Rand-Hendriksen K, Shah K, Ramos-Go\u00f1i JM, Luo N. EuroQol protocols for time trade-off valuation of health outcomes. PharmacoEconomics. 2016;34:993\u20131004.","journal-title":"PharmacoEconomics"},{"key":"2335_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10198-013-0503-2","volume":"14","author":"BM Janssen","year":"2013","unstructured":"Janssen BM, Oppe M, Versteegh MM, Stolk EA. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ. 2013;14:5\u201313.","journal-title":"Eur J Health Econ"},{"issue":"6","key":"2335_CR29","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza LS, Stewart KD, Lloyd AJ, Rowen D, Brazier JE. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 2021;24(6):812\u201321.","journal-title":"Value Health"},{"issue":"3","key":"2335_CR30","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/hec.1596","volume":"20","author":"NJ Devlin","year":"2011","unstructured":"Devlin NJ, Tsuchiya A, Buckingham K, Tilling C. A uniform time trade off method for states better and worse than dead: feasibility study of the \u2018lead time\u2019 approach. Health Econ. 2011;20(3):348\u201361.","journal-title":"Health Econ"},{"key":"2335_CR31","unstructured":"United States Census Bureau. 2020 Census Results 2020 [Available from: https:\/\/www.census.gov\/en.html"},{"issue":"3","key":"2335_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","volume":"22","author":"J Brazier","year":"2019","unstructured":"Brazier J, Ara R, Azzabi I, et al. Identification, review, and Use of Health State Utilities in cost-effectiveness models: an ISPOR Good practices for Outcomes Research Task Force Report. Value Health. 2019;22(3):267\u201375.","journal-title":"Value Health"},{"issue":"4","key":"2335_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/02729890122062622","volume":"21","author":"GW Torrance","year":"2001","unstructured":"Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making: Int J Soc Med Decis Mak. 2001;21(4):329\u201334.","journal-title":"Med Decis Making: Int J Soc Med Decis Mak"},{"issue":"Suppl 1","key":"2335_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40273-021-01115-5","volume":"40","author":"CS Sutherland","year":"2022","unstructured":"Sutherland CS, Hudson P, Mitchell S, Paracha N. Systematic Literature Review to identify Utility values in patients with spinal muscular atrophy (SMA) and their caregivers. PharmacoEconomics. 2022;40(Suppl 1):39\u201367.","journal-title":"PharmacoEconomics"},{"key":"2335_CR35","doi-asserted-by":"publisher","first-page":"S713","DOI":"10.1016\/j.jval.2020.08.1867","volume":"23","author":"B Nafees","year":"2020","unstructured":"Nafees B, de Freitas H, Lloyd A, Olaye A, Pang F. PRO131 a Societal Utility Study to Elicit Values for Stages of Metachromatic Leukodystrophy (MLD) in the United Kingdom. Value Health. 2020;23:S713.","journal-title":"Value Health"},{"issue":"4","key":"2335_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s40273-019-00873-7","volume":"38","author":"D Rowen","year":"2020","unstructured":"Rowen D, Rivero-Arias O, Devlin N, Ratcliffe J. Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in child and adolescent populations: where are we now and where are we going? PharmacoEconomics. 2020;38(4):325\u201340.","journal-title":"PharmacoEconomics"},{"key":"2335_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1477-7525-12-48","volume":"12","author":"LS Matza","year":"2014","unstructured":"Matza LS, Boye KS, Feeny DH, Johnston JA, Bowman L, Jordan JB. Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions. Health Qual Life Outcomes. 2014;12:48.","journal-title":"Health Qual Life Outcomes"},{"key":"2335_CR38","unstructured":"U.S. Bureau of Labor Statistics. Labor Force Statistics from the Current Population Survey [updated January 25, 2023. Available from: https:\/\/www.bls.gov\/cps\/aa2022\/cpsaat01.htm"},{"key":"2335_CR39","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen B, Cabases J. Self-reported population health: an international perspective based on EQ-5D. 2014.","DOI":"10.1007\/978-94-007-7596-1"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-025-02335-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-025-02335-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-025-02335-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:44:10Z","timestamp":1737629050000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-025-02335-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2335"],"URL":"https:\/\/doi.org\/10.1186\/s12955-025-02335-5","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and declared exempt by an Institutional Review Board (Western Institutional Review Board, WIRB, July 2023). All participants provided informed consent prior to the interviews. The study complied with the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RZ, PC and IT are employees of PTC Therapeutics, Inc. KF, GNC and AL are employees of Acaster Lloyd Consulting Ltd which was contracted by PTC Therapeutics for the conduct of this study. BM received consulting fees from PTC Therapeutics, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}